Working… Menu

Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03327831
Recruitment Status : Completed
First Posted : October 31, 2017
Last Update Posted : December 15, 2017
Information provided by (Responsible Party):
Christopher Zachary, University of California, Irvine

Brief Summary:
Photodynamic therapy is an effective treatment for actinic keratoses. In the United States topical aminolevulinic acid (ALA) is approved as a photosensitizing agent for this treatment, and it has traditionally been activated with the use of an in-office artificial light source. This clinical trial seeks to measure the safety and efficacy of using natural sunlight to activate the ALA.

Condition or disease Intervention/treatment Phase
Actinic Keratosis Drug: Aminolevulinic Acid Phase 4

Detailed Description:
  • Initial Visit:

    • study inclusion criteria reviewed
    • consent forms reviewed
    • creation of facial map for actinic keratoses
    • face cleansed with chlorhexidine soap
    • light curettage of precancerous skin lesions
    • application of topical aminolevulinic acid (ALA)
    • application of sunscreen
    • patient then spends 2 hours outdoors in a shaded area
    • after treatment the patient is to remain indoors for 48 hours
  • 3 month follow up visit

    - facial map of actinic keratoses used to document treatment response

  • 6 month follow up visit

    • facial map of actinic keratoses used to document treatment response

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
Study Start Date : April 2015
Actual Primary Completion Date : February 2017
Actual Study Completion Date : July 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Open Label Treatment Arm
This study has a single, open label treatment arm. Patients will have topical aminolevulinic acid applied to the actinic keratoses in the treatment area (face/scalp) and will spend 2 hours outdoors in the shade to activate the medication. The patient then follow up in clinic 3 months and 6 months after their treatment to have the number of actinic keratoses counted.
Drug: Aminolevulinic Acid
Topical application followed by activation by ambient sunlight
Other Name: Kerastick

Primary Outcome Measures :
  1. The change in the number of Actinic Keratoses [ Time Frame: 0, 3, and 6 months ]
    The the change in number of actinic keratoses at time 0 and 6 months treatment will be measured as the primary outcome

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: 0, 3, and 6 months ]
    Measurement of crusting, erythema, edema, and pain

  2. Lux Correlation [ Time Frame: 0, 3, and 6 months ]
    Ambient lux from sunlight is measured during treatment and will be analyzed to determine if it contributes to treatment efficacy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Clinical diagnosis of >10 actinic keratoses on head and neck
  • Age ≥ 18 years (Because no dosing or adverse event data are currently available on the use of topical aminolevulinic acid in patients <18 years of age, children are excluded from this study)
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

  • Patients currently undergoing anti-neoplastic therapy including but not limited to the following:

    • Topical imiquimod
    • Topical 5-fluorouracil
    • Topical ingenol mebutate
    • Topical diclofenac
    • Topical retinoids
    • Oral acitretin
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid
  • Patients with a known photosensitivity disorder including but not limited to porphyria, lupus, polymorphous light eruption, or immunobullous disease.
  • Patients taking known photosensitizing medications including but not limited to griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines.
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03327831

Layout table for location information
United States, California
University of California, Irvine
Irvine, California, United States, 92697-2400
Sponsors and Collaborators
University of California, Irvine
Layout table for investigator information
Principal Investigator: Christopher B Zachary, MBBS. FRC[ University of California, Irvine
Layout table for additonal information
Responsible Party: Christopher Zachary, Principal Investigator, University of California, Irvine Identifier: NCT03327831    
Other Study ID Numbers: 2015-1889
First Posted: October 31, 2017    Key Record Dates
Last Update Posted: December 15, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Christopher Zachary, University of California, Irvine:
aminolevulinic acid
photodynamic therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents